SCHEMBL894991

SCHEMBL894991

O=C(O)c1c(Nc2ccc(C(=O)N3CCOCC3)cc2)cc(Cl)nc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.50
JAK2 O60674 2/20 0.50
PHGDH O43175 1/20 0.49
HPGD P15428 5/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
HTT P42858 2/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TTK P33981 1/20 0.47
PKM P14618 1/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
JAK3 P52333 1/20 0.46
AKR1C3 P42330 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
EPHX2 P34913 1/20 0.45
ATM Q13315 1/20 0.45
PTK2 Q05397 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL894648 0.90 JAK2 (0.49) LRRK2JAK2PHGDHHPGDALDH1A1
SCHEMBL894790 0.80 LRRK2 (0.53) LRRK2JAK2PHGDHHPGDALDH1A1
SCHEMBL893873 0.76 LRRK2 (0.47) LRRK2JAK2HPGDMAPTPKM
SCHEMBL10168724 0.76 MAPT (0.47) HPGDALDH1A1MAPTHTTSMN1; SMN2
SCHEMBL894658 0.76 JAK2 (0.54) LRRK2JAK2PHGDHHPGDALDH1A1
SCHEMBL894614 0.75 CSF1R (0.55) LRRK2JAK2PHGDHHPGDALDH1A1
SCHEMBL3993564 0.72 PHGDH (0.63) JAK2PHGDHHPGDNPC1SMN1; SMN2
SCHEMBL798155 0.71 PHGDH (0.60) PHGDHHPGDALDH1A1MAPTHTT
SCHEMBL894622 0.71 GAA (0.52) LRRK2JAK2HPGDALDH1A1MAPT
SCHEMBL893942 0.70 BTK (0.65) LRRK2JAK2PHGDHHPGDJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
EP-2440204-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS Bristol-Myers Squibb Company (US) 2012-04-18 EP disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
WO-2010144647-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-12-16 WO disclosed
WO-2010144647-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT LRRK2 614/4885JAK2 123/4885PHGDH 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.